| DrugRepV_0323 | Clemastine | Respiratory System | Sneezing, rhinorrhea, pruritus and acrimation | Ebola virus | EBOV-eGFP | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 27622822 |
| DrugRepV_0369 | Azelastine | Respiratory System | Rhinitis | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0373 | Ciclesonide | Respiratory System | Allergic rhinitis | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0375 | Clemastine Fumarate | Respiratory System | Allergic rhinitis | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0383 | Doxylamine Succinate | Respiratory System | Cough, vomiting and nausea | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0394 | Methdilazine Hydrochloride | Respiratory System | Hypersensitivity reactions | Skin disorders | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0422 | Astemizole | Respiratory System | Allergies | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0427 | Clemastine | Respiratory System | Allergic rhinitis | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0450 | Astemizole | Respiratory System | Allergies | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0454 | Clemastine | Respiratory System | Allergic rhinitis | Ebola virus | eGFP-EBOV | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26041706 |
| DrugRepV_0478 | Astemizole | Respiratory System | Allergies | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0483 | Clemastine | Respiratory System | Allergic rhinitis | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0526 | Clemastine | Respiratory System | Allergic rhinitis | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0561 | Bitolterol | Respiratory System | Bronchodilator | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Withdrawn | 26038505 |
| DrugRepV_0568 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | Approved | 26038505 |
| DrugRepV_0610 | Dexbrompheniramine | Respiratory System | Allergies | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (74 %) | Approved | 23577127 |
| DrugRepV_0613 | Diphenylpyraline | Respiratory System | Allergies | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (22 %) | Approved | 23577127 |
| DrugRepV_0619 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (33 %) | Approved | 23577127 |
| DrugRepV_0633 | Diphenylpyraline | Respiratory System | Allergies | Lassa virus | Josiah | NA | Real-time PCR | No significant effect | Approved | 23577127 |
| DrugRepV_0639 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Lassa virus | Josiah | NA | Real-time PCR | No significant effect | Approved | 23577127 |
| DrugRepV_0649 | Dexbrompheniramine | Respiratory System | Allergies | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (80 %) | Approved | 23577127 |
| DrugRepV_0652 | Diphenylpyraline | Respiratory System | Allergies | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (85 %) | Approved | 23577127 |
| DrugRepV_0658 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (97 %) | Approved | 23577127 |
| DrugRepV_0673 | Dexbrompheniramine | Respiratory System | Allergies | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (85 %) | Approved | 23577127 |
| DrugRepV_0676 | Diphenylpyraline | Respiratory System | Allergies | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (96 %) | Approved | 23577127 |
| DrugRepV_0682 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (99 %) | Approved | 23577127 |
| DrugRepV_0698 | Diphenylpyraline | Respiratory System | Allergies | Ebola virus | EBOLA-eGFP | NA | Fluorescence-based assay | Decrease | Approved | 23577127 |
| DrugRepV_0704 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Ebola virus | EBOLA-eGFP | NA | Fluorescence-based assay | Decrease | Approved | 23577127 |
| DrugRepV_0815 | Ciclesonide | Respiratory System | Allergic rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (66.46 %) | Approved | 27476412 |
| DrugRepV_0816 | Meclizine Dihydrochloride | Respiratory System | Nausea | Vomiting | Motion sickness | Vertigo | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (57.685 %) | Approved | 27476412 |
| DrugRepV_0866 | Acrivastine | Respiratory System | Allergic rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.315 %) | Approved | 27476412 |
| DrugRepV_0884 | Oxtriphylline | Respiratory System | Asthma | Bronchospasm | Chronic Obstructive Pulmonary Disease (COPD) | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (58.265 %) | Approved | 27476412 |
| DrugRepV_0919 | Metaproterenol Hemisulfate | Respiratory System | NA | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.225 %) | Approved | 27476412 |
| DrugRepV_0975 | Fexofenadine Hydrochloride | Respiratory System | Allergic rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.055 %) | Approved | 27476412 |
| DrugRepV_0978 | Formoterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.97 %) | Approved, Investigational | 27476412 |
| DrugRepV_0981 | Aminophylline | Respiratory System | Asthma, bronchospasm and Chronic Obstructive Pulmonary Disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.325 %) | Approved | 27476412 |
| DrugRepV_0994 | Chlorpheniramine Maleate | Respiratory System | Rhinitis, urticaria, allergy, common cold, asthma and hay fever | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.605 %) | Approved | 27476412 |
| DrugRepV_1037 | Dyphylline | Respiratory System | Chronic bronchitis and emphysema | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.825 %) | Approved | 27476412 |
| DrugRepV_1086 | Doxapram Hydrochloride Hydrate | Respiratory System | Obstructive pulmonary disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.45 %) | Approved | 27476412 |
| DrugRepV_1087 | Cetirizine Hydrochloride | Respiratory System | Allergic rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.565 %) | Approved | 27476412 |
| DrugRepV_1091 | Ipratropium bromide | Respiratory System | Asthma | Chronic bronchitis | Emphysema | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.345 %) | Approved, Experimental | 27476412 |
| DrugRepV_1114 | Zafirlukast | Respiratory System | Asthma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.94 %) | Approved | 27476412 |
| DrugRepV_1123 | Flunisolide | Respiratory System | Asthma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.785 %) | Approved, Investigational | 27476412 |
| DrugRepV_1125 | Levalbuterol Hydrochloride | Respiratory System | Chronic obstructive pulmonary disease | Asthma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.305 %) | Approved, Investigational | 27476412 |
| DrugRepV_1144 | Dexchlorpheniramine Maleate | Respiratory System | Allergic rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.11 %) | Approved | 27476412 |
| DrugRepV_1204 | Amlexanox | Respiratory System | Asthma and rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.71 %) | Approved | 27476412 |
| DrugRepV_1231 | Azelastine Hydrochloride | Respiratory System | Rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.96 %) | Approved | 27476412 |
| DrugRepV_1237 | Salbutamol Hemisulfate | Respiratory System | Bronchial asthma | Chronic bronchitis | Chronic bronchopulmonary disorders | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.66 %) | Approved | 27476412 |
| DrugRepV_1254 | Theophylline | Respiratory System | Chronic asthma | Chronic lung diseases, such as emphysema and chronic bronchitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.835 %) | Approved | 27476412 |
| DrugRepV_1280 | Brompheniramine Maleate | Respiratory System | Allergies, rhinitis and urticaria | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.015 %) | Approved | 27476412 |
| DrugRepV_1285 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.11 %) | Approved | 27476412 |
| DrugRepV_1293 | Trimethobenzamide Hydrochloride | Respiratory System | Nausea | Vomiting | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.125 %) | Approved, Investigational | 27476412 |
| DrugRepV_1296 | Levocetirizine Dihydrochloride | Respiratory System | Allergic rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.885 %) | Approved | 27476412 |
| DrugRepV_1335 | Promethazine Hydrochloride | Respiratory System | Allergic disorders | Nausea/vomiting | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.26 %) | Approved, Investigational | 27476412 |
| DrugRepV_1363 | Montelukast Sodium | Respiratory System | Asthma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.9 %) | Approved | 27476412 |
| DrugRepV_1388 | Tiotropium Bromide | Respiratory System | Chronic obstructive pulmonary disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.135 %) | Approved | 27476412 |
| DrugRepV_1404 | Ketotifen Fumarate | Respiratory System | Atopic asthma | Conjunctivitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.43 %) | Approved | 27476412 |
| DrugRepV_1425 | Fluticasone propionate | Respiratory System | Asthma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.92 %) | Approved | 27476412 |
| DrugRepV_1426 | Terbutaline Hemisulfate | Respiratory System | Bronchospasm | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.52 %) | Approved | 27476412 |
| DrugRepV_1463 | Dextromethorphan | Respiratory System | Cough | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.605 %) | Approved | 27476412 |
| DrugRepV_1480 | Clemastine Fumarate | Respiratory System | Allergic rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (39.7 %) | Approved | 27476412 |
| DrugRepV_1498 | Desloratadine | Respiratory System | Allergic rhinitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (38.02 %) | Approved | 27476412 |
| DrugRepV_1502 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (36.42 %) | Approved | 27476412 |
| DrugRepV_1507 | Loratadine | Respiratory System | Rhinitis | Urticaria | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (40.655 %) | Approved, Investigational | 27476412 |
| DrugRepV_1520 | Cyproheptadine Hydrochloride Sesquihydrate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (34.41 %) | Approved | 27476412 |
| DrugRepV_1578 | Clemastine Fumarate | Respiratory System | Allergic rhinitis | Rift Valley fever virus | MP12-Luc | NA | Luciferase reporter assay | Decrease (63 %) | Approved | 26217313 |
| DrugRepV_1983 | Promethazine Hydrochloride | Respiratory System | Allergic disorders | Nausea/vomiting | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_1984 | Astemizole | Respiratory System | Allergies | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_1985 | Chlorphenoxamine Hydrochloride | Respiratory System | Parkinson's | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_1987 | Thiethylperazine Maleate | Respiratory System | Nausea | Vomiting | Mildly emetic cancer chemotherapy agents | Radiation therapy | Toxins | Middle East respiratory syndrome coronavirus | Jordan | NA | Enzyme-linked immunosorbent assay | Decrease (50 %) | Approved, Withdrawn | 24841273 |
| DrugRepV_2007 | Promethazine Hydrochloride | Respiratory System | Allergic disorders | Nausea/vomiting | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Approved, Investigational | 24841273 |
| DrugRepV_2008 | Astemizole | Respiratory System | Allergies | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_2009 | Chlorphenoxamine Hydrochloride | Respiratory System | Parkinson's | Severe acute respiratory syndrome coronavirus | NA | NA | Cytopathic effect (CPE) assay | Decrease (50 %) | Withdrawn | 24841273 |
| DrugRepV_2017 | Clemastine | Respiratory System | Allergic rhinitis | Ebola virus | Zaire strain-pEBOV | NA | Firefly luciferase assay | Decrease (50 %) | Approved | 26585243 |
| DrugRepV_2025 | Pimethixene Maleate | Respiratory System | NA | Ebola virus | Zaire strain-pEBOV | NA | Firefly luciferase assay | Decrease (50 %) | Approved | 26585243 |
| DrugRepV_2072 | Chlorcyclizine | Respiratory System | Allergic rhinitis | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2074 | Chlorcyclizine | Respiratory System | Allergic rhinitis | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2075 | Cetirizine | Respiratory System | Allergic rhinitis | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved | 29981374 |
| DrugRepV_2076 | Cetirizine | Respiratory System | Allergic rhinitis | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved | 29981374 |
| DrugRepV_2077 | Fexofenadine | Respiratory System | Allergic rhinitis | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved, Investigational | 29981374 |
| DrugRepV_2078 | Fexofenadine | Respiratory System | Allergic rhinitis | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved, Investigational | 29981374 |
| DrugRepV_2089 | Chlorphenoxamine | Respiratory System | Parkinson's | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Withdrawn | 29981374 |
| DrugRepV_2090 | Chlorphenoxamine | Respiratory System | Parkinson's | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Withdrawn | 29981374 |
| DrugRepV_2091 | Carbinoxamine | Respiratory System | Allergic rhinitis | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2092 | Carbinoxamine | Respiratory System | Allergic rhinitis | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2093 | Doxylamine | Respiratory System | Allergies and an antitussive, antiemetic, and hypnotic | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2094 | Doxylamine | Respiratory System | Allergies and an antitussive, antiemetic, and hypnotic | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | No significant decrease (50 %) | Approved | 29981374 |
| DrugRepV_2097 | Cyclizine | Respiratory System | Nausea, vomiting, and dizziness | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2098 | Cyclizine | Respiratory System | Nausea, vomiting, and dizziness | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2099 | Buclizine | Respiratory System | Nausea, vomiting, and dizziness | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2100 | Buclizine | Respiratory System | Nausea, vomiting, and dizziness | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2101 | Meclizine | Respiratory System | Nausea | Vomiting | Motion sickness | Vertigo | Ebola virus | HIV/EBOV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2102 | Meclizine | Respiratory System | Nausea | Vomiting | Motion sickness | Vertigo | Marburg virus | HIV/MARV | NA | Luciferase reporter assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2104 | Chlorcyclizine | Respiratory System | Allergic rhinitis | Ebola virus | EBOV/kikwit | NA | Immunoblot assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2106 | Chlorcyclizine | Respiratory System | Allergic rhinitis | Ebola virus | EBOV/kikwit | NA | Immunoblot assay | Decrease (50 %) | Approved | 29981374 |
| DrugRepV_2180 | Azelastine Hydrochloride | Respiratory System | Rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (14.2513127 %) | Approved | 27742486 |
| DrugRepV_2199 | Brompheniramine | Respiratory System | Allergies, rhinitis and urticaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (9.75770133 %) | Approved | 27742486 |
| DrugRepV_2216 | Pranlukast | Respiratory System | Allergic reaction | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.56691777 %) | Approved | 27742486 |
| DrugRepV_2238 | Clemastine Fumarate | Respiratory System | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.50989786 %) | Approved | 27742486 |
| DrugRepV_2279 | Cyproheptadine Hydrochloride | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.78644356 %) | Approved | 27742486 |
| DrugRepV_2286 | Roflumilast | Respiratory System | Chronic Obstructive Pulmonary Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.69383115 %) | Approved | 27742486 |
| DrugRepV_2307 | Loratadine | Respiratory System | Rhinitis | Urticaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (4.27362909 %) | Approved, Investigational | 27742486 |
| DrugRepV_2340 | Formoterol Hemifumarate | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (3.36046959 %) | Approved, Investigational | 27742486 |
| DrugRepV_2371 | Bromhexine Hydrochloride | Respiratory System | Respiratory disorder | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.68488038 %) | Approved | 27742486 |
| DrugRepV_2377 | Azatadine Dimaleate | Respiratory System | Respiratory mucosal congestion and allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.55959216 %) | Approved | 27742486 |
| DrugRepV_2379 | Fluticasone propionate | Respiratory System | Asthma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.49959478 %) | Approved | 27742486 |
| DrugRepV_2385 | Meclizine Dihydrochloride | Respiratory System | Nausea | Vomiting | Motion sickness | Vertigo | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.40144725 %) | Approved | 27742486 |
| DrugRepV_2406 | Mizolastine | Respiratory System | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.16794907 %) | Investigational | 27742486 |
| DrugRepV_2491 | Guaifenesin | Respiratory System | Cold | Bronchitis or other breathing illnesses | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.24064615 %) | Approved, Investigational, Vet approved | 27742486 |
| DrugRepV_2516 | Ketotifen Fumarate | Respiratory System | Atopic asthma | Conjunctivitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.1370416 %) | Approved | 27742486 |
| DrugRepV_2581 | Salbutamol Sulfate | Respiratory System | Bronchial asthma | Chronic bronchitis | Chronic bronchopulmonary disorders | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.3636934 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2595 | Erdosteine | Respiratory System | Chronic bronchitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-1.5223486 %) | Approved | 27742486 |
| DrugRepV_2649 | Aminophylline | Respiratory System | Asthma, bronchospasm and Chronic Obstructive Pulmonary Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1683375 %) | Approved | 27742486 |
| DrugRepV_2655 | Dyphylline | Respiratory System | Chronic bronchitis and emphysema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.2577836 %) | Approved | 27742486 |
| DrugRepV_2669 | Cetirizine Dihydrochloride | Respiratory System | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.4358768 %) | Approved | 27742486 |
| DrugRepV_2691 | Ipratropium bromide | Respiratory System | Asthma | Chronic bronchitis | Emphysema | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.8135236 %) | Approved, Experimental | 27742486 |
| DrugRepV_2694 | Chlorpheniramine Maleate | Respiratory System | Rhinitis, urticaria, allergy, common cold, asthma and hay fever | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.8794966 %) | Approved | 27742486 |
| DrugRepV_2715 | Indacaterol Maleate | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.2126007 %) | Approved | 27742486 |
| DrugRepV_2759 | Tiotropium Bromide Hydrate | Respiratory System | Chronic obstructive pulmonary disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-4.1287058 %) | Approved | 27742486 |
| DrugRepV_2867 | Fexofenadine Hydrochloride | Respiratory System | Allergic rhinitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-7.3594321 %) | Approved | 27742486 |
| DrugRepV_3530 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/Puerto Rico/8/1934(H1N1) |  | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3531 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/Guizhou/54/1989(H3N2) | | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3532 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/Shanghai/37T/2009(H1N1) | | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3533 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | B/Shanghai/2017(BY) | | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3534 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/H7N9/4664T/2013 (H7N9) | | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3535 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/Puerto Rico/8/1934(H1N1) | | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3536 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/Guizhou/54/1989(H3N2) | | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3537 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/Shanghai/37T/2009(H1N1) | | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3538 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | B/Shanghai/2017(BY) | | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3539 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/H7N9/4664T/2013 (H7N9) | | CPE reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3540 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/Shanghai/37T/2009(H1N1) | | Plaque reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3541 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/Guizhou/54/1989(H3N2) | | Plaque reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3542 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/Shanghai/37T/2009(H1N1) | | Plaque reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3543 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/Guizhou/54/1989(H3N2) | | Plaque reduction assay | Decrease (50 %) | Approved | 30459739 |
| DrugRepV_3544 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/PR/8/1934 (H1N1) | | Real-time PCR | Decrease (90 %) | Approved | 30459739 |
| DrugRepV_3545 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/PR/8/1934 (H1N1) | | Real-time PCR | Decrease (80 %) | Approved | 30459739 |
| DrugRepV_3546 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/PR/8/1934 (H1N1) | | Indirect immunofluorescence assay | Decrease | Approved | 30459739 |
| DrugRepV_3547 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/PR/8/1934 (H1N1) | | Indirect immunofluorescence assay | Decrease | Approved | 30459739 |
| DrugRepV_3548 | Carbinoxamine maleate | Respiratory System | Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis | Influenza virus | A/Shanghai/4664T/2013(H7N9) | | Survival assay | Increase | Approved | 30459739 |
| DrugRepV_3549 | Chlorpheniramine Maleate | Respiratory System | Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma | Influenza virus | A/Shanghai/4664T/2013(H7N9) | | Survival assay | Increase | Approved | 30459739 |
| DrugRepV_5432 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Influenza virus | A/Puerto Rico/8/34 (PR8) | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5433 | Dextromethorphan | Respiratory System | Cough | Influenza virus | A/Puerto Rico/8/34 (PR8) | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5436 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Influenza virus | pdm09A/Mexico/InDRE4487/2009 | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5437 | Dextromethorphan | Respiratory System | Cough | Influenza virus | pdm09A/Mexico/InDRE4487/2009 | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5440 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Influenza virus | A/Victoria/36/2011 | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5441 | Dextromethorphan | Respiratory System | Cough | Influenza virus | A/Victoria/36/2011 | | Plaque reduction assay | Decrease (50 %) | Approved | 31244822 |
| DrugRepV_5444 | Dextromethorphan | Respiratory System | Cough | Influenza virus | A/Puerto Rico/8/34 (PR8) | | Virus inhibition assay | Decrease (5.7 log) | Approved | 31244822 |
| DrugRepV_5445 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Influenza virus | A/Puerto Rico/8/34 (PR8) | | Virus inhibition assay | Decrease (5.8 log) | Approved | 31244822 |
| DrugRepV_5448 | Dextromethorphan | Respiratory System | Cough | Influenza virus | pdm09A/Mexico/InDRE4487/2009 | | Virus inhibition assay | Decrease (5.5 log) | Approved | 31244822 |
| DrugRepV_5449 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Influenza virus | pdm09A/Mexico/InDRE4487/2009 | | Virus inhibition assay | Decrease (5.1 log) | Approved | 31244822 |
| DrugRepV_5452 | Dextromethorphan | Respiratory System | Cough | Influenza virus | A/Victoria/36/2011 | | Virus inhibition assay | Decrease (5.3 log) | Approved | 31244822 |
| DrugRepV_5453 | Ketotifen | Respiratory System | Atopic asthma | Conjunctivitis | Influenza virus | A/Victoria/36/2011 | | Virus inhibition assay | Decrease (5.5 log) | Approved | 31244822 |
| DrugRepV_5484 | Chlorcyclizine | Respiratory System | Allergic rhinitis | Zika virus | NA | NA | MTT assay | Decrease (50 %) | Approved | 31850756 |
| DrugRepV_5485 | Pranlukast | Respiratory System | Allergic reaction | Zika virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved | 31786251 |
| DrugRepV_5731 | Benzethonium | Respiratory System | Topical microbial infections | Dengue virus | New Guinea C | | Fluorescence-based assay | Decrease (50 %) | Approved | 20973722 |
| DrugRepV_5732 | Benzethonium | Respiratory System | Topical microbial infections | Dengue virus | New Guinea C | | Fluorescence-based assay | Decrease (50 %) | Approved | 20973722 |
| DrugRepV_5862 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Dengue virus | NA | | Plaque assay | Decrease (50 %) | Approved | 27572397 |
| DrugRepV_5865 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Dengue virus | NA | | Western blot | Decrease (Decrease Band intensity) | Approved | 27572397 |
| DrugRepV_5868 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Dengue virus | NA | | Real-time PCR | Decrease (99 Fold) | Approved | 27572397 |
| DrugRepV_5871 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Dengue virus | NA | | Immunoflourescence assay | Decrease (0 %) | Approved | 27572397 |
| DrugRepV_5874 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Dengue virus | NA | | Real-time PCR | Decrease (<10 Fold) | Approved | 27572397 |
| DrugRepV_5877 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Dengue virus | NA | | Plaque assay | Decrease (2.5 Fold) | Approved | 27572397 |
| DrugRepV_5880 | Salmeterol | Respiratory System | Asthma | Chronic obstructive pulmonary disease | Dengue virus | NA | | Real-time PCR | Decrease (> 95 %) | Approved | 27572397 |
| DrugRepV_6012 | Cromolyn | Respiratory System | Allergies and Asthma | Dengue virus | Eden2 | | Plaque assay | Increase | Approved | 23638300 |
| DrugRepV_7588 | Ivacaftor | Respiratory System | Cystic fibrosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (50 %) | Approved | 32438446 |
| DrugRepV_7589 | Ivacaftor | Respiratory System | Cystic fibrosis | SARS Coronavirus-2 | ?CoV/KOR/KCDC03/2020) | NA | Immunofluorescence | Decrease (90 %) | Approved | 32438446 |
| DrugRepV_7685 | Ipratropium bromide | Respiratory System | Asthma | Chronic bronchitis | Emphysema | SARS Coronavirus-2 | | NA | NA | Decrease (50 %) | Approved, Experimental | 32577649 |
| DrugRepV_7711 | Astemizole | Respiratory System | Allergies | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Withdrawn | 32707573 |
| DrugRepV_7725 | Astemizole | Respiratory System | Allergies | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Withdrawn | 32707573 |
| DrugRepV_7738 | Astemizole | Respiratory System | Allergies | SARS Coronavirus-2 | SARS-CoV-2-USA-WA1/2020 | NA | Immunofluorescence | Decrease (50 %) | Withdrawn | 32707573 |
| DrugRepV_8238 | Ivacaftor | Respiratory System | Cystic fibrosis | Vaccinia virus | NA | | NA | Decrease (75.5 %) | Approved | 32708182 |
| DrugRepV_8240 | Fexofenadine Hydrochloride | Respiratory System | Allergic rhinitis | Vaccinia virus | NA | | NA | Decrease (10.5 %) | Approved | 32708182 |